New Treatment for Dry Eye

Supporting research into a better treatment for dry eye has been one of Dr. Jerome Wujek’s tasks for the past eight years and has just begun to reach fruition with the launch of an FDA-approved Phase I clinical trial that will test the safety and efficacy of a novel drug called P-321 Ophthalmic Solution. The drug is applied as an eye drop and targets a unique mechanism involved in maintaining moisture in the eye. Its development was supported through two NEI SBIR grants to Parion Sciences, Inc. and through the NCATS Bridging Interventional Development Gaps (BrIDGs) program, which gives investigators access to NIH subcontractors who conduct preclinical safety studies necessary for an FDA Investigational New Drug (IND) application. Read more.